The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
If approved, lying in wait for Vraylar in the treatment-resistant depression category will be Johnson & Johnson's Spravato (esketamine), which was approved by the FDA in 2019, albeit with a label ...